Rezultati - Roessig, Lothar
- Showing 1 - 18 results of 18
-
1
Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure od Watanabe-Fujinuma, Emi, Origasa, Hideki, Bamber, Luke, Roessig, Lothar, Toyoda, Tetsumi, Haga, Yuri, Gwaltney, Chad, Pieske, Burkert
Izdano 2020Text -
2
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction od Ruehs, Hauke, Klein, Dagmar, Frei, Matthias, Grevel, Joachim, Austin, Rupert, Becker, Corina, Roessig, Lothar, Pieske, Burkert, Garmann, Dirk, Meyer, Michaela
Izdano 2021Text -
3
Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction od Kramer, Frank, Voss, Sebastian, Roessig, Lothar, Igl, Bernd‐Wolfgang, Butler, Javed, Lam, Carolyn S.P., Maggioni, Aldo P., Shah, Sanjiv J., Pieske, Burkert
Izdano 2020Text -
4
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction od Greene, Stephen J., Gheorghiade, Mihai, Borlaug, Barry A., Pieske, Burkert, Vaduganathan, Muthiah, Burnett, John C., Roessig, Lothar, Stasch, Johannes‐Peter, Solomon, Scott D., Paulus, Walter J., Butler, Javed
Izdano 2013Text -
5
Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, S... od Bonderman, Diana, Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Jansa, Pavel, Rosenkranz, Stephan, Tufaro, Caroline, Bojic, Andja, Lam, Carolyn S. P., Frey, Reiner, Ochan Kilama, Michael, Unger, Sigrun, Roessig, Lothar, Lang, Irene M.
Izdano 2014Text -
6
Defining changes in physical limitation from the patient perspective: insights from the VITALITY‐HFpEF randomized trial od Butler, Javed, Spertus, John A., Bamber, Luke, Khan, Muhammad Shahzeb, Roessig, Lothar, Vlajnic, Vanja, Norquist, Josephine M., Anstrom, Kevin J., Blaustein, Robert O., Lam, Carolyn S.P., Armstrong, Paul W.
Izdano 2022Text -
7
Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure od Frydas, Athanasios, Morris, Daniel A., Belyavskiy, Evgeny, Radhakrishnan, Aravind‐Kumar, Kropf, Martin, Tadic, Marijana, Roessig, Lothar, Lam, Carolyn S.P., Shah, Sanjiv J., Solomon, Scott D., Pieske, Burkert, Pieske‐Kraigher, Elisabeth
Izdano 2020Text -
8
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRES... od Pieske, Burkert, Maggioni, Aldo P., Lam, Carolyn S.P., Pieske-Kraigher, Elisabeth, Filippatos, Gerasimos, Butler, Javed, Ponikowski, Piotr, Shah, Sanjiv J., Solomon, Scott D., Scalise, Andrea-Viviana, Mueller, Katharina, Roessig, Lothar, Gheorghiade, Mihai
Izdano 2017Text -
9
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial od Lam, Carolyn S. P., Mulder, Hillary, Lopatin, Yuri, Vazquez‐Tanus, Jose B., Siu, David, Ezekowitz, Justin, Pieske, Burkert, O’Connor, Christopher M., Roessig, Lothar, Patel, Mahesh J., Anstrom, Kevin J., Hernandez, Adrian F., Armstrong, Paul W.
Izdano 2021Text -
10
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study od Rossing, Peter, Burgess, Ellen, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Gillard, Pieter, MacIsaac, Richard J., Wainstein, Julio, Joseph, Amer, Brinker, Meike, Roessig, Lothar, Scott, Charlie, Bakris, George L.
Izdano 2022Text -
11
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial od Lam, Carolyn S. P., Giczewska, Anna, Sliwa, Karen, Edelmann, Frank, Refsgaard, Jens, Bocchi, Edimar, Ezekowitz, Justin A., Hernandez, Adrian F., O’Connor, Christopher M., Roessig, Lothar, Patel, Mahesh J., Pieske, Burkert, Anstrom, Kevin J., Armstrong, Paul W.
Izdano 2020Text -
12
Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps od Mentz, Robert J., Roessig, Lothar, Greenberg, Barry H., Sato, Naoki, Shinagawa, Kaori, Yeo, Daniel, Kwok, Bernard W.K., Reyes, Eugenio B., Krum, Henry, Pieske, Burkert, Greene, Stephen J., Ambrosy, Andrew P., Kelly, Jacob P., Zannad, Faiez, Pitt, Bertram, Lam, Carolyn S.P.
Izdano 2016Text -
13
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subject... od Voors, Adriaan A., Mulder, Hillary, Reyes, Eugene, Cowie, Martin R., Lassus, Johan, Hernandez, Adrian F., Ezekowitz, Justin A., Butler, Javed, O'Connor, Christopher M., Koglin, Joerg, Lam, Carolyn S.P., Pieske, Burkert, Roessig, Lothar, Ponikowski, Piotr, Anstrom, Kevin J., Armstrong, Paul W.
Izdano 2021Text -
14
Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries od Greene, Stephen J., Shah, Ami N., Butler, Javed, Ambrosy, Andrew P., Anker, Stefan D., Chioncel, Ovidiu, Collins, Sean P., Dinh, Wilfried, Dunnmon, Preston M., Fonarow, Gregg C., Lam, Carolyn S. P., Mentz, Robert J., Pieske, Burkert, Roessig, Lothar, Rosano, Giuseppe M. C., Sato, Naoki, Vaduganathan, Muthiah, Gheorghiade, Mihai
Izdano 2014Text -
15
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial od Armstrong, Paul W., Lam, Carolyn S. P., Anstrom, Kevin J., Ezekowitz, Justin, Hernandez, Adrian F., O’Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Shah, Sanjiv J., Solomon, Scott D., Voors, Adriaan A., She, Lilin, Vlajnic, Vanja, Carvalho, Francine, Bamber, Luke, Blaustein, Robert O., Roessig, Lothar, Butler, Javed
Izdano 2020Text -
16
Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials od Coles, Theresa M., Hernandez, Adrian F., Reeve, Bryce B., Cook, Karon, Edwards, Michael C., Boutin, Marc, Bush, Elizabeth, Degboe, Arnold, Roessig, Lothar, Rudolph, Amy, McNulty, Pauline, Patel, Nikunj, Kay-Mugford, Trish, Vernon, Margaret, Woloschak, Michael, Buchele, Gustavo, Spertus, John A., Roe, Matthew T., Bury, Denise, Weinfurt, Kevin
Izdano 2021Text -
17
Developing Therapies for Heart Failure with Preserved Ejection Fraction: Current State and Future Directions od Butler, Javed, Fonarow, Gregg C., Zile, Michael R., Lam, Carolyn S., Roessig, Lothar, Schelbert, Erik B., Shah, Sanjiv J., Ahmed, Ali, Bonow, Robert O., Cleland, John GF, Cody, Robert J., Chioncel, Ovidiu, Collins, Sean P., Dunnmon, Preston, Filippatos, Gerasimos, Lefkowitz, Martin P., Marti, Catherine N., McMurray, John J., Misselwitz, Frank, Nodari, Savina, O’Connor, Christopher, Pfeffer, Marc A., Pieske, Burkert, Pitt, Bertram, Rosano, Guiseppe, Sabbah, Hani N., Senni, Michele, Solomon, Scott D., Stockbridge, Norman, Teerlink, John R., Georgiopoulou, Vasiliki V., Gheorghiade, Mihai
Izdano 2014Text -
18
Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations od Butler, Javed, Hamo, Carine E., Udelson, James E., O’Connor, Christopher, Sabbah, Hani N., Metra, Marco, Shah, Sanjiv J., Kitzman, Dalane W., Teerlink, John, Bernstein, Harold S., Brooks, Gabriel, Depre, Christophe, DeSouza, Mary M., Dinh, Wilfried, Donovan, Mark, Frische-Danielson, Regina, Frost, Robert J., Garza, Dahlia, Gohring, Udo-Michael, Hellawell, Jennifer, Hsia, Judith, Ishihara, Shiro, Kay-Mugford, Patricia, Koglin, Joerg, Kozinn, Marc, Larson, Christopher J., Mayo, Martha, Gan, Li-Ming, Mugnier, Pierrre, Mushonga, Sekayi, Roessig, Lothar, Russo, Cesare, Salsali, Afshin, Satler, Carol, Shi, Victor, Ticho, Barry, van der Laan, Michael, Yancy, Clyde, Stockbridge, Norman, Gheorghiade, Mihai
Izdano 2017Text